Bacteriophage reduces biofilm of Staphylococcus aureus ex vivo isolates from chronic rhinosinusitis patients

American Journal of Rhinology and Allergy

Volumn 28, Issue 1, 2014, Pages 3-11

  Drilling, Amanda ^a,b   Morales, Sandra ^c   Jardeleza, Camille ^a,b   Vreugde, Sarah ^a,b   Speck, Peter ^d   Wormald, Peter John ^a,b  

^a QUEEN ELIZABETH HOSPITAL   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c Special Phage Services Pty Ltd   (Australia)

^d FLINDERS UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIUM ISOLATE; BACTERIUM MUTANT; BIOFILM; BIOMASS; CHRONIC RHINOSINUSITIS; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; EX VIVO STUDY; FLUORESCENCE ANALYSIS; HUMAN; IN VITRO STUDY; NONHUMAN; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS PHAGE; BACTERIAL LOAD; BACTERIOLYSIS; BIOLOGICAL THERAPY; CHRONIC DISEASE; COMPLICATION; CONFOCAL MICROSCOPY; GROWTH, DEVELOPMENT AND AGING; MICROBIOLOGY; RHINITIS; SINUSITIS; STAPHYLOCOCCAL INFECTIONS; VIROLOGY;

BACTERIAL LOAD; BACTERIOLYSIS; BIOFILMS; BIOLOGICAL THERAPY; CHRONIC DISEASE; HUMANS; MICROSCOPY, CONFOCAL; RHINITIS; SINUSITIS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS PHAGES;

EID: 84893366626     PISSN: 19458924     EISSN: 19458932     Source Type: Journal    
DOI: 10.2500/ajra.2014.28.4001     Document Type: Article

References (80)

1. Sylvester DC, Carr S, and Nix P. Maximal medical therapy for chronic rhinosinusitis: A survey of otolaryngology consultants in the United Kingdom. Int Forum Allergy Rhinol 3:129-132, 2013.
2. Dubin MG, Liu C, Lin SY, and Senior BA. American Rhinologic Society member survey on "maximal medical therapy" for chronic rhinosinusitis. Am J Rhinol 21:483-488, 2007. (Pubitemid 47360038)
3. Kaszuba SM, and Stewart MG. Medical management and diagnosis of chronic rhinosinusitis: A survey of treatment patterns by United States otolaryngologists. Am J Rhinol 20:186-190, 2006.
4. Henderson DK. Managing methicillin-resistant staphylococci: A paradigm for preventing nosocomial transmission of resistant organisms. Am J Infect Control 34:S46-S54, 2006. (Pubitemid 43928179)
5. Mulligan ME, Murray-Leisure KA, Ribner BS, et al. Methicillin-resistant Staphylococcus aureus: a consensus review of the microbiology, pathogenesis, and epidemiology with implications for prevention and management. Am J Med 94:313-328, 1993. (Pubitemid 23074805)
6. Nickel JC, Ruseska I, Wright JB, and Costerton JW. Tobramycin resistance of Pseudomonas aeruginosa cells growing as a biofilm on urinary catheter material. Antimicrob Agents Chemother 27:619-624, 1985. (Pubitemid 15097672)
7. Gravitz L. Turning a new phage. Nat Med 18:1318-1320, 2012.
8. Singhal D, Psaltis AJ, Foreman A, and Wormald PJ. The impact of biofilms on outcomes after endoscopic sinus surgery. Am J Rhinol Allergy 24:169-174, 2010.
9. Madeo J, and Frieri M. Bacterial biofilms and chronic rhinosinusitis. Allergy Asthma Proc 34:335-341, 2013.
10. Costerton JW, Lewandowski Z, Caldwell DE, et al. Microbial biofilms. Annu Rev Microbiol 49:711-745, 1995.
11. Flemming HC, and Wingender J. The biofilm matrix. Nat Rev Microbiol 8:623-633, 2010.
12. Hsin CH, Su MC, Tsao CH, et al. Bacteriology and antimicrobial susceptibility of pediatric chronic rhinosinusitis: A 6-year result of maxillary sinus punctures. Am J Otolaryngol 31:145-149, 2010.
13. Doyle PW, and Woodham JD. Evaluation of the microbiology of chronic ethmoid sinusitis. J Clin Microbiol 29:2396-2400, 1991.
14. Finegold SM, Flynn MJ, Rose FV, et al. Bacteriologic findings associated with chronic bacterial maxillary sinusitis in adults. Clin Infect Dis 35:428-433, 2002. (Pubitemid 34852573)
15. George DL, Falk PS, Umberto Meduri G, et al. Nosocomial sinusitis in patients in the medical intensive care unit: A prospective epidemiological study. Clin Infect Dis 27:463-470, 1998. (Pubitemid 28421991)
16. Slack CL, Dahn KA, Abzug MJ, and Chan KH. Antibiotic-resistant bacteria in pediatric chronic sinusitis. Pediatr Infect Dis J 20:247-250, 2001. (Pubitemid 32240261)
17. Brook I. Aerobic and anaerobic bacterial flora of normal maxillary sinuses. Laryngoscope 91:372-376, 1981. (Pubitemid 11155278)
18. Kingdom TT, and Swain RE Jr. The microbiology and antimicrobial resistance patterns in chronic rhinosinusitis. Am J Otolaryngol 25: 323-328, 2004. (Pubitemid 39149942)
19. Busaba NY, Siegel NS, and Salman SD. Microbiology of chronic ethmoid sinusitis: Is this a bacterial disease? Am J Otolaryngol 25: 379-384, 2004. (Pubitemid 39488288)
20. Sanderson AR, Leid JG, and Hunsaker D. Bacterial biofilms on the sinus mucosa of human subjects with chronic rhinosinusitis. Laryngoscope 116:1121-1126, 2006. (Pubitemid 44317935)
21. Singhal D, Foreman A, Jervis-Bardy J, et al. Staphylococcus aureus biofilms: Nemesis of endoscopic sinus surgery. Laryngoscope 121: 1578-1583, 2011.
22. Zernotti ME, Angel Villegas N, Roques Revol M, et al. Evidence of bacterial biofilms in nasal polyposis. J Investig Allergol Clin Immunol 20:380-385, 2010.
23. You H, Zhuge P, Li D, et al. Factors affecting bacterial biofilm expression in chronic rhinosinusitis and the influences on prognosis. Am J Otolaryngol 32:583-590, 2011.
24. Psaltis AJ, Ha KR, Beule AG, et al. Confocal scanning laser microscopy evidence of biofilms in patients with chronic rhinosinusitis. Laryngoscope 117:1302-1306, 2007. (Pubitemid 47015686)
25. Jervis-Bardy J, Foreman A, Field J, and Wormald PJ. Impaired mucosal healing and infection associated with Staphylococcus aureus after endoscopic sinus surgery. Am J Rhinol Allergy 23:549-552, 2009.
26. Ramesh V, Fralick JA, and Rolfe RD. Prevention of Clostridium difficile-induced ileocecitis with Bacteriophage. Anaerobe 5:69-78, 1999. (Pubitemid 29431598)
27. Barrow P, Lovell M, and Berchieri A. Use of lytic bacteriophage for control of experimental Escherichia coli septicemia and meningitis in chickens and calves. Clin Diagn Lab Immunol 5:294-298, 1998. (Pubitemid 28246447)
28. Matsuzaki S, Yasuda M, Nishikawa H, et al. Experimental protection of mice against lethal Staphylococcus aureus infection by novel bacteriophage phi MR11. J Infect Dis 187:613-624, 2003. (Pubitemid 36250025)
29. Wills QF, Kerrigan C, and Soothill JS. Experimental bacteriophage protection against Staphylococcus aureus abscesses in a rabbit model. Antimicrob Agents Chemother 49:1220-1221, 2005. (Pubitemid 40327754)
30. McVay CS, Velásquez M, and Fralick JA. Phage therapy of Pseudomonas aeruginosa infection in a mouse burn wound model. Antimicrob Agents Chemother 51:1934-1938, 2007. (Pubitemid 46903076)
31. Capparelli R, Parlato M, Borriello G, et al. Experimental phage therapy against Staphylococcus aureus in mice. Antimicrob Agents Chemother 51:2765-2773, 2007. (Pubitemid 47206211)
32. Cerveny KE, DePaola A, Duckworth DH, and Gulig PA. Phage therapy of local and systemic disease caused by Vibrio vulnificus in iron-dextran-treated mice. Infect Immun 70:6251-6262, 2002. (Pubitemid 35192717)
33. Soothill JS. Bacteriophage prevents destruction of skin grafts by Pseudomonas aeruginosa. Burns 20:209-211, 1994. (Pubitemid 24163010)
34. Fu W, Forster T, Mayer O, et al. Bacteriophage cocktail for the prevention of biofilm formation by Pseudomonas aeruginosa on catheters in an in vitro model system. Antimicrob Agents Chemother 54:397-404, 2010.
35. Carson L, Gorman SP, and Gilmore BF. The use of lytic bacteriophages in the prevention and eradication of biofilms of Proteus mirabilis and Escherichia coli. FEMS Immunol Med Microbiol 59: 447-455, 2010.
36. Sillankorva S, Oliveira R, Vieira MJ, et al. Bacteriophage Phi S1 infection of Pseudomonas fluorescens planktonic cells versus biofilms. Biofouling 20:133-138, 2004. (Pubitemid 39533597)
37. Siringan P, Connerton PL, Payne RJ, and Connerton IF. Bacteriophage- mediated dispersal of Campylobacter jejuni biofilms. Appl Environ Microbiol 77:3320-3326, 2011.
38. Hanlon GW, Denyer SP, Olliff CJ, and Ibrahim LJ. Reduction in exopolysaccharide viscosity as an aid to bacteriophage penetration through Pseudomonas aeruginosa biofilms. Appl Environ Microbiol 67:2746-2753, 2001. (Pubitemid 33639753)
39. Cerca N, Oliveira R, and Azeredo J. Susceptibility of Staphylococcus epidermidis planktonic cells and biofilms to the lytic action of Staphylococcus bacteriophage K. Lett Appl Microbiol 45:313-317, 2007. (Pubitemid 47294735)
40. Curtin JJ, and Donlan RM. Using bacteriophages to reduce formation of catheter-associated biofilms by Staphylococcus epidermidis. Antimicrob Agents Chemother 50:1268-1275, 2006.
41. Lu TK, and Collins JJ. Dispersing biofilms with engineered enzymatic bacteriophage. Proc Natl Acad Sci U S A 104:11197-11202, 2007. (Pubitemid 47175118)
42. Tait K, Skillman LC, and Sutherland IW. The efficacy of bacteriophage as a method of biofilm eradication. Biofouling 18:305-311, 2002. (Pubitemid 35211866)
43. Sharma M, Ryu JH, and Beuchat LR. Inactivation of Escherichia coli O157:H7 in biofilm on stainless steel by treatment with an alkaline cleaner and a bacteriophage. J Appl Microbiol 99:449-459, 2005. (Pubitemid 41215822)
44. Rahman M, Kim S, Kim SM, et al. Characterization of induced Staphylococcus aureus bacteriophage SAP-26 and its anti-biofilm activity with rifampicin. Biofouling 27:1087-1093, 2011.
45. Merril CR, Scholl D, and Adhya SL. The prospect for bacteriophage therapy in Western medicine. Nat Rev Drug Discov 2:489-497, 2003. (Pubitemid 37361729)
46. Bradbury J. My enemy's enemy is my friend. Using phages to fight bacteria. Lancet 363:624-625, 2004. (Pubitemid 38264183)
47. Merabishvili M, Pirnay JP, Verbeken G, et al. Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. PLoS One 4:e4944, 2009.
48. O'Flynn G, Ross RP, Fitzgerald GF, and Coffey A. Evaluation of a cocktail of three bacteriophages for biocontrol of Escherichia coli O157:H7. Appl Environ Microbiol 70:3417-3424, 2004. (Pubitemid 38745886)
49. Jardeleza C, Foreman A, Baker L, et al. The effects of nitric oxide on Staphylococcus aureus biofilm growth and its implications in chronic rhinosinusitis. Allergy Rhinol 6:438-444, 2011.
50. Jepson CD, and March JB. Bacteriophage lambda is a highly stable DNA vaccine delivery vehicle. Vaccine 22:2413-2419, 2004. (Pubitemid 38757338)
51. Heydorn A, Nielsen AT, Hentzer M, et al. Quantification of biofilm structures by the novel computer program COMSTAT. Microbiology 146:2395-2407, 2000.
52. Singhal D, Boase S, Field J, et al. Quantitative analysis of in vivo mucosal bacterial biofilms. Int Forum Allergy Rhinol 2:57-62, 2012.
53. Adams M. Colicins and Other Bacteriocins. In Bacteriophages. New York, NY: Interscience Publishers, Inc., 382-384, 1959.
54. Tanji Y, Shimada T, Yoichi M, et al. Toward rational control of Escherichia coli O157:H7 by a phage cocktail. Appl Microbiol Biotechnol 64:270-274, 2004. (Pubitemid 38553695)
55. Pal C, Maciá MD, Oliver A, et al. Coevolution with viruses drives the evolution of bacterial mutation rates. Nature 450:1079-1081, 2007. (Pubitemid 350273608)
56. Briandet R, Lacroix-Gueu P, Renault M, et al. Fluorescence correlation spectroscopy to study diffusion and reaction of bacteriophages inside biofilms. Appl Environ Microbiol 74:2135-2143, 2008. (Pubitemid 351522068)
57. Sutherland IW, Hughes KA, Skillman LC, and Tait K. The interaction of phage and biofilms. FEMS Microbiol Lett 232:1-6, 2004. (Pubitemid 38328727)
58. Stummeyer K, Schwarzer D, Claus H, et al. Evolution of bacteriophages infecting encapsulated bacteria: Lessons from Escherichia coli K1-specific phages. Mol Microbiol 60:1123-1135, 2006.
59. Kimura K, and Itoh Y. Characterization of poly-gamma-glutamate hydrolase encoded by a bacteriophage genome: Possible role in phage infection of Bacillus subtilis encapsulated with poly-gammaglutamate. Appl Environ Microbiol 69:2491-2497, 2003. (Pubitemid 36560321)
60. Cornelissen A, Ceyssens PJ, T'Syen J, et al. The T7-related Pseudomonas putida phage phi15 displays virion-associated biofilm degradation properties. PLoS One 6:e18597, 2011.
61. Hughes KA, Sutherland IW, Clark J, and Jones MV. Bacteriophage and associated polysaccharide depolymerases - Novel tools for study of bacterial biofilms. J Appl Microbiol 85:583-590, 1998. (Pubitemid 28419363)
62. Abuladze T, Li M, Menetrez MY, et al. Bacteriophages reduce experimental contamination of hard surfaces, tomato, spinach, broccoli, and ground beef by Escherichia coli O157:H7. Appl Environ Microb 74:6230-6238, 2008.
63. Higgins JP, Higgins SE, Guenther KL, et al. Use of a specific bacteriophage treatment to reduce Salmonella in poultry products. Poultry Sci 84:1141-1145, 2005. (Pubitemid 41097344)
64. Nordström K, and Forsgren A. Effect of protein A on adsorption of bacteriophages to Staphylococcus aureus. J Virol 14:198-202, 1974.
65. Labrie SJ, Samson JE, and Moineau S. Bacteriophage resistance mechanisms. Nat Rev Microbiol 8:317-327, 2010.
66. Waldron DE, and Lindsay JA. Sau: A novel line age-specific type I restriction-modification system that blocks horizontal gene transfer into Staphylococcus aureus and between S. aureus isolates of different lineages. J Bacteriol 188:5578-5585, 2006. (Pubitemid 44157315)
67. Gómez P, and Buckling A. Bacteria-phage antagonistic coevolution in soil. Science 332:106-109, 2011.
68. Hall AR, De Vos D, Friman VP, et al. Effects of sequential and simultaneous applications of bacteriophages on populations of Pseudomonas aeruginosa in vitro and in wax moth larvae. Appl Environ Microbiol 78:5646-5652, 2012.
69. Buckling A, and Rainey PB. Antagonistic coevolution between a bacterium and a bacteriophage. Proc Biol Sci 269:931-936, 2002. (Pubitemid 34518136)
70. Brüssow H. Bacteriophage therapy: Potential and problems. In Encyclopedia of Microbiology. Moselio S (Ed). Oxford: Academic Press, 267-273, 2009.
71. Park B, Iwase T, and Liu GY. Intranasal application of S. epidermidis prevents colonization by methicillin-resistant Staphylococcus aureus in mice. PLoS One 6:e25880, 2011.
72. Lina G, Boutite F, Tristan A, et al. Bacterial competition for human nasal cavity colonization: Role of Staphylococcal agr alleles. Appl Environ Microbiol 69:18-23, 2003. (Pubitemid 36077452)
73. Uehara Y, Nakama H, Agematsu K, et al. Bacterial interference among nasal inhabitants: Eradication of Staphylococcus aureus from nasal cavities by artificial implantation of Corynebacterium sp. J Hosp Infect 44:127-133, 2000. (Pubitemid 30120501)
74. Le T, Psaltis A, Tan LW, and Wormald PJ. The efficacy of topical antibiofilm agents in a sheep model of rhinosinusitis. Am J Rhinol 22:560-567, 2008.
75. Singhal D, Jekle A, Debabov D, et al. Efficacy of NVC-422 against Staphylococcus aureus biofilms in a sheep biofilm model of sinusitis. Int Forum Allergy Rhinol 2:309-315, 2012.
76. Kutter E, De Vos D, Gvasalia G, et al. Phage therapy in clinical practice: Treatment of human infections. Curr Pharm Biotechnol 11:69-86, 2010.
77. Tan NC, Foreman A, Jardeleza C, et al. Intracellular Staphylococcus aureus: The Trojan horse of recalcitrant chronic rhinosinusitis? Int Forum Allergy Rhinol 3:261-266, 2013.
78. Wood AJ, Fraser JD, Swift S, et al. Intramucosal bacterial microcolonies exist in chronic rhinosinusitis without inducing a local immune response. Am J Rhinol Allergy 26:265-270, 2012.
79. Tan NC, Tran HB, Foreman A, et al. Identifying intracellular Staphylococcus aureus in chronic rhinosinusitis: a direct comparison of techniques. Am J Rhinol Allergy 26:444-449, 2012.
80. Broxmeyer L, Sosnowska D, Miltner E, et al. Killing of Mycobacterium avium and Mycobacterium tuberculosis by a mycobacteriophage delivered by a nonvirulent mycobacterium: A model for phage therapy of intracellular bacterial pathogens. J Infect Dis 186:1155-1160, 2002. (Pubitemid 35177119)